OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press10210.17650/1818-8346-2011-6-1-30-34HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CAREГЕМОБЛАСТОЗЫ: ДИАГНОСТИКА, ЛЕЧЕНИЕ, СОПРОВОДИТЕЛЬНАЯ ТЕРАПИЯTreatment of non-Hodgkin lymphoma and mature В-cell acute leukemia in children and adolescents: data of Russian regional hospitalsЛечение неходжкинских лимфом и острого лейкоза из зрелых В-клеток у детей и подростков по данным региональных российских клиникSamochatovaYe. V.СамочатоваЕ. В.
Russian Federation
samochatova@niidg.ruShelikhovaL. N.ШелиховаЛ. Н.
Russian Federation
Federal Research Center of Pediatric Hematology, Oncology and ImmunologyФГУ Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии Минздравсоцразвития РоссииRussian Children Clinical HospitalРоссийская детская клиническая больница2402201161303424072014240720142011https://oncohematology.abvpress.ru/ongm/article/view/102

The article presents treatment results of 233 patients (children and adolescents under 19 years old; median — 8.76 years) with CD20-positive non-Hodgkin lymphomas and B-cell acute leukemia (B-NHL/B-AL) received chemotherapy (BFM B-NHL 90–95 protocols) or combined chemo-immunotherapy with rituximab (B-NHL-2004mab protocol). Combined chemo-immunotherapy was used for patients with Burkitt lymphoma, diffuse large cells lymphomas stage III–IV and B-AL, and included cytoreductive phase, 6 polychemotherapy (PCT) courses and rituximab. PCT courses are similar to those of original BFM B-NHL90 protocol, except for the first 2 courses, where daily methotrexate dose was reduced from 5 to 1 g/m2/24 h. Rituximab infused IV 12 hours before the start of first 4 chemotherapy courses at a dose of 375 mg/m2. The data in the questionnaires form have been submitted from 28 pediatric specialized hospitals from 27 Russia regions over the past 5 years (2005–2009). Protocol with rituximab has proved to be more effective than chemotherapy alone. The authors discuss the possibility of using combined chemo-immunotherapy for the treatment of B-NHL/B-AL at regional hospitals and the prospects for further treatment results improvement in this group of tumors.

childrenB-cell non-Hodgkin lymphomatarget therapyдетиВ-клеточные неходжкинские лимфомытаргетная терапия1. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Jaffe E.S., Harris N.L., Stein H., Vardiman J.W. Lyon, 2001; p.181Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Jaffe E.S., Harris N.L., Stein H., Vardiman J.W. Lyon, 2001; p.1812. Magrath I. The non-Hodgkin’s lymphomas in children. In Oxford Textbook of Oncology. Oxford Medical Publications, Oxford, 1995; p. 1809–51.Magrath I. The non-Hodgkin’s lymphomas in children. In Oxford Textbook of Oncology. Oxford Medical Publications, Oxford, 1995; p. 1809–51.3. Patte C., Philip T., Rodary C. et al. High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol 1991;9:123–32.Patte C., Philip T., Rodary C. et al. High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol 1991;9:123–32.4. Goldman S., Gerard M., Sposto R. et al. Exellent results in children and adolescents with isolated mature B-cell acute lymphoblastic leukemia (B-ALL) (Burkitt): Report from the FAB International LMB study FAB/LMB 96. Proc Am Hem 2005;106;Abstract 234:72a.Goldman S., Gerard M., Sposto R. et al. Exellent results in children and adolescents with isolated mature B-cell acute lymphoblastic leukemia (B-ALL) (Burkitt): Report from the FAB International LMB study FAB/LMB 96. Proc Am Hem 2005;106;Abstract 234:72a.5. Reiter A., Schrappe M., Tiemann M. et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt- Munster Group Trial NHL-BFM-90. Blood 1999;94(10):3294–306.Reiter A., Schrappe M., Tiemann M. et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt- Munster Group Trial NHL-BFM-90. Blood 1999;94(10):3294–306.6. Самочатова Е.В., Островская А.В., Карачунский А.И. и соавт. Значение верификации варианта неходжкинской лимфомы у детей для эффективности лечения по современным протоколам. Гематол и трансфузиол 2000;6:9–14.Самочатова Е.В., Островская А.В., Карачунский А.И. и соавт. Значение верификации варианта неходжкинской лимфомы у детей для эффективности лечения по современным протоколам. Гематол и трансфузиол 2000;6:9–14.7. Самочатова Е.В., Алейникова О.В., Беликова Л.Ю., Боридко А.Н. и соавт. Неходжкинские лимфомы у детей: клиническая характеристика, возможности диагностики и терапии (по данным клиник России и Беларуси). Гематол и трансфузиол 2001;1:1–10.Самочатова Е.В., Алейникова О.В., Беликова Л.Ю., Боридко А.Н. и соавт. Неходжкинские лимфомы у детей: клиническая характеристика, возможности диагностики и терапии (по данным клиник России и Беларуси). Гематол и трансфузиол 2001;1:1–10.8. Островская А.В. Неходжкинские лимфомы у детей. Автореферат дис. … канд. мед. наук. М., 2004.Островская А.В. Неходжкинские лимфомы у детей. Автореферат дис. … канд. мед. наук. М., 2004.9. Minard-Colin V., Horikawa M., Xiu Y. Immune effector mechanisms of CD20 monoclonal antibodies. Hematology meeting reports 2009;3(5):19.Minard-Colin V., Horikawa M., Xiu Y. Immune effector mechanisms of CD20 monoclonal antibodies. Hematology meeting reports 2009;3(5):19.10. Pfreundshuh M.G.M. et al. Randomized intergroup trial of first-line treatment for patients < 60 years with diffuse large B-cell lymphoma (DLBCL) with a CHOP-like regimen with and without the anti-CD20 antibody rituximab — early stopping after first interim analysis. Blood 2002;11:A65.Pfreundshuh M.G.M. et al. Randomized intergroup trial of first-line treatment for patients < 60 years with diffuse large B-cell lymphoma (DLBCL) with a CHOP-like regimen with and without the anti-CD20 antibody rituximab — early stopping after first interim analysis. Blood 2002;11:A65.11. Coiffer B., Lepage E., Brier J. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002;346:235.Coiffer B., Lepage E., Brier J. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002;346:235.12. Samochatova E., Myakova N., Shelikhova L. et al. Preliminary results of treatment of pediatric advance-staged mature В-cell non-Hodgkin lymphomas/B-ALL with intensive chemotherapy + rituximab: effectiveness and toxicity. Pediatric Blood & Cancer 2006;46(issue7):854.Samochatova E., Myakova N., Shelikhova L. et al. Preliminary results of treatment of pediatric advance-staged mature В-cell non-Hodgkin lymphomas/B-ALL with intensive chemotherapy + rituximab: effectiveness and toxicity. Pediatric Blood & Cancer 2006;46(issue7):854.13. Самочатова Е.В., Шелихова Л.Н., Белогурова М.Б., Шамардина А.В. и соавт. Комбинированная химиоиммунотерапия больных неходжкинскими лимфомами из зрелых В-клеток возрастной группы до 18 лет: результаты многоцентрового исследования НХЛ 2004 М с применением ритуксимаба и модифицированного протокола В-НХЛ БФМ-90. Онкогематол 2009;3:4–14.Самочатова Е.В., Шелихова Л.Н., Белогурова М.Б., Шамардина А.В. и соавт. Комбинированная химиоиммунотерапия больных неходжкинскими лимфомами из зрелых В-клеток возрастной группы до 18 лет: результаты многоцентрового исследования НХЛ 2004 М с применением ритуксимаба и модифицированного протокола В-НХЛ БФМ-90. Онкогематол 2009;3:4–14.